7 completed. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Primate Diseases: new trials by email Literature Review of Primate Diseases trials Research Report on Primate Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults cAd3-Marburg vaccine, Placebo - Marburg Virus Disease | Phase 2 | Completed | Albert B. Sabin Vaccine Institute | 126 | 2023-10-19 | 2025-07-23 |
| A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines BNT166a - Monkeypox | Phase 1 / Phase 2 | Completed | BioNTech SE | 96 | 2023-09-21 | 2026-09-15 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age mRNA-1769, Placebo - Smallpox, Mpox | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 351 | 2023-08-15 | 2025-07-16 |
| A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox JYNNEOS - Monkeypox | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 450 | 2023-03-22 | 2026-03-27 |
| Tecovirimat for Treatment of Monkeypox Virus Tecovirimat Oral Capsule, Placebo - Monkeypox | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 597 | 2022-10-10 | 2025-10-09 |
| Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine JYNNEOS - Monkeypox | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 229 | 2022-09-09 | 2026-04-16 |
| Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine - Smallpox, Monkeypox | Phase 2 / Phase 3 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 334 | 2021-10-01 | 2023-05-06 |
Mpox, Monkeypox (6) · Smallpox (2) · Cowpox (1) · Marburg Virus Disease (1)
Animal Diseases (7) · Infections (7) · Virus Diseases (7) · DNA Virus Infections (6) · Poxviridae Infections (6) · Rodent Diseases (6) · Filoviridae Infections (1) · Hemorrhagic Fevers, Viral (1) · Monkey Diseases (1) · Mononegavirales Infections (1) · RNA Virus Infections (1)
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (2) · tecovirimat (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Albert B. Sabin Vaccine Institute (1) · BioNTech SE (1) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (1) · ModernaTX, Inc. (1)
United States (3) · United Kingdom (2) · Democratic Republic of the Congo (1) · Kenya (1) · Puerto Rico (1) · Russia (1) · Uganda (1)
Irina V Krasil'nikova, PhD (1) · Jean-Jacques Muyembe-Tamfum, MD PhD (1) · Vladimir I. Kuzubov, PhD (1)
PMID 38366591, PMID 40239067, PMID 41319397, PMID 42235570, PMID 42532635